µÏÍþ¹ú¼Ê

    • µÏÍþÖƵÏÍþ¹ú¼Ê µÏÍþÖƵÏÍþ¹ú¼Ê

    ¼ò ¤™
    • ¼ò
    • ·±
    • EN
    ¤œ
    Ïà¹ØÁ´½Ó
    • ½­ËÕºÀÉ­µÏÍþ¹ú¼ÊÒµ¼¯ÍÅÓÐÏÞ¹«Ë¾¥Y
    ÐÂÎÅ·¢²¼
    Press Release
    Ê×Ò³  >  ÐÂÎÅÖÐÐÄ  >  ÐÂÎÅ·¢²¼
    µÏÍþÖƵÏÍþ¹ú¼ÊÊ¥ÂÞÀ³?ÖÎÁÆ·Ç͸ÎöCKDƶѪ»¼ÕߢóÆÚÁÙ´²Ñо¿ÔÚ¹ú¼ÊÆÚ¿¯Kidney International Reports·¢²¼
    ·¢²¼ÈÕÆÚ£º2024/12/25
    ×ÖºÅ

    ½üÈÕ£¬¹ú¼ÊÉöÔಡÁìÓòÖøÃûÆÚ¿¯Kidney International Reports£¨IF£º5.7/Q1)ÔÚÏß·¢±íÁËÓɹ㶫ʡÈËÃñÒ½ÔºÓàѧÇå½ÌÊÚǣͷµÄÅàĪɳëÄ×¢ÉäÒº£¨ÉÌÆ·Ãû£ºÊ¥ÂÞÀ³?£©ÔÚ·Ç͸ÎöÉöÐÔƶѪ»¼ÕßÖпªÕ¹µÄ¢óÆÚÁÙ´²Ñо¿Êý¾Ý¡£

    Ê¥ÂÞÀ³?ÊÇÄ¿Ç°È«ÇòΨһ»ñÅúÉÏÊеÄEPOÄ£ÄâëÄ£¬ÆäÕë¶Ô͸ÎöÉöÐÔƶѪ»¼ÕߵĢóÆÚ×¢²áÁÙ´²Ñо¿½á¹ûÒÑÓÚ2023Äê10ÔÂÔÚÁøÒ¶µ¶×Ó¿¯eClinicalMedicineÉÏ·¢±í1¡£¸ÃÑо¿±íÃ÷ÿÔÂ1´ÎƤÏÂ×¢ÉäÅàĪɳëÄÖÎÁÆÖйú͸Îö»¼ÕßƶѪ£¬ÔÚÁÆЧÉÏ·ÇÁÓÓÚ³£¹æÿÖÜ1~3´Î°¢·¨ÒÀ²´Í¡ÖÎÁÆ£¬ÉõÖÁ¾ßÓиüÓŵÄÇ÷ÊÆ£¬ÇÒ°²È«ÐÔÏ൱1¡£

    ´Ë´ÎKidney International Reports·¢±íµÄÊ¥ÂÞÀ³? ÖÎÁÆ·Ç͸ÎöCKDƶѪ»¼ÕߢóÆÚÁÙ´²Ñо¿ÏÔʾ£¬ÔÚÖйú·Ç͸ÎöÉöÐÔƶѪ»¼ÕßÖУ¬ÅàĪɳëĽöÐè4ÖÜ1´ÎƤÏÂ×¢É䣬¾ÍÄÜ´ïµ½Óë³£¹æ°¢·¨ÒÀ²´Í¡Í¬ÑùÁÆЧ£¬ÇÒÐÄѪ¹Ü²»Á¼Ê¼þ·¢ÉúÂʸüµÍ2£¬Õ⽫ΪÅàĪɳëÄÔÚ·Ç͸ÎöCKDƶѪ»¼ÕßÖеÄÓ¦ÓÃÌṩÓÐÁ¦Ö§³Ö£¬¾ßÌåÐÅÏ¢ÈçÏ¡£

    Ñо¿½éÉÜ




    ÅàĪɳëÄÖÎÁÆ·Ç͸ÎöCKD»¼ÕßƶѪµÄËæ»úÊÔÑé

    ×÷Õߣº¹ã¶«Ê¡ÈËÃñÒ½ÔºÓàѧÇå½ÌÊÚ  µÈ

    ÏòÉÏ»¬¶¯ÔÄÀÀ

    ¡¾Ñо¿·½·¨¡¿

    ÕâÏîΪÆÚ52ÖܵĶàÖÐÐÄ¡¢Ëæ»ú¡¢¿ª·Å±êÇ©¡¢ÑôÐÔ¶ÔÕÕ¡¢·ÇÁÓЧÐÔIIIÆÚÁÙ´²Ñо¿£¬¹²ÄÉÈëÀ´×Ô¹úÄÚ38¸öÖÐÐĵÄ173Àýδ½ÓÊܹýºìϸ°ûÉú³É´Ì¼¤¼Á£¨ESA£©ÖÎÁƵķÇ͸ÎöÂýÐÔÉöÔಡ£¨CKD-NDD£©Ïà¹ØƶѪ»¼Õߣ¬Ö¼ÔÚÆÀ¹ÀÅàĪɳëÄ£¨³õʼ¼ÁÁ¿0.04mg/kg£¬Æ¤ÏÂ×¢É䣬4ÖÜ1´Î£©¶Ô±È°¢·¨ÒÀ²´Í¡£¨³õʼ¼ÁÁ¿6000IU/ÖÜ£¬Æ¤ÏÂ×¢É䣬ÿ1~2ÖÜ1´Î£©ÖÎÁÆ52ÖܵÄÁÆЧºÍ°²È«ÐÔ¡£Ö÷ÒªÁÆЧÖÕµãΪÁÆЧÆÀ¹ÀÆÚ£¨µÚ17~24ÖÜ£©Ñªºìµ°°×£¨HGB£©Æ½¾ùÖµÏà¶Ô»ùÏߵı仯ֵ£¨?HGB£©¡£

    ¡¾Ñо¿½á¹û¡¿

    ½á¹ûÏÔʾ£¬ÔÚÈ«·ÖÎö¼¯£¨FAS£©ÖУ¬ÅàĪɳëÄ×éÁÆЧÆÀ¹ÀÆÚHb×Ô»ùÏßƽ¾ùÉý¸ß19.2 g/L£¬°¢·¨ÒÀ²´Í¡×éÔòƽ¾ùÉý¸ß15.4g/L£¬Á½×é²îÒìΪ3.8 g/L£¨95% CI£¬0.7-6.9£¬P= 0.02£©£¬´ïµ½Ô¤ÉèµÄ·ÇÁÓ±ê×¼¡£ÔÚƶѪ»ñµÃ¾ÀÕýºó£¬Ïà±È¶ÔÕÕ×飬ÅàĪɳëÄ×éÓиü¶àµÄ»¼ÕßHbˮƽһֱά³ÖÔÚ100~120g/LµÄÄ¿±ê·¶Î§£¨15.9%vs5.9%£©£¬ÕâÌáʾÅàĪɳëĸüÓÐÖúÓÚʵÏÖ³¤ÆÚ³ÖÐø´ï±ê¡£´ËÍ⣬Ïà±È¶ÔÕÕ×飬ÅàĪɳëÄ×éÐèÒª½ÏÉٵļÁÁ¿µ÷Õû´ÎÊý¾ÍÄÜʵÏÖHb´ï±ê¡£

    °²È«ÐÔ·½Ã棬Á½×é×ÜÌåÉϲ»Á¼Ê¼þ·¢ÉúÂÊÏ൱£¬µ«ÅàĪɳëÄ×éÖÎÁÆÏà¹Ø²»Á¼Ê¼þ£¨AE£©·¢ÉúÂʸüµÍ£¨19.1% vs 29.3%£©¡£ÖµµÃ×¢ÒâµÄÊÇ£¬ÅàĪɳëÄ×éµÄ¸´ºÏ°²È«ÐÔʼþ£¨0.9% vs 3.4%£©ºÍÆäËûÐÄѪ¹Üʼþ·¢ÉúÂÊ£¨0% vs 5.2%£©¾ùµÍÓÚ°¢·¨ÒÀ²´Í¡×é¡£´ËÍ⣬ÅàĪɳëÄ×éδ³öÏÖÓëÑо¿µÏÍþ¹ú¼ÊÎïÏà¹ØµÄ¹ýÃô·´Ó¦£¬Ò²Î´³öÏÖÆäËû·ÇÔ¤ÆÚÑÏÖز»Á¼·´Ó¦Ê¼þ¡£

    ¡¾Ñо¿½áÂÛ¡¿

    ¸ÃÑо¿±íÃ÷£¬ÔÚÖйú·Ç͸ÎöÉöÐÔƶѪ»¼ÕßÖУ¬ÅàĪɳëĽöÐè4ÖÜ1´ÎƤÏÂ×¢É䣬¾ÍÄÜ´ïµ½Óë³£¹æ°¢·¨ÒÀ²´Í¡Í¬ÑùÁÆЧ£¬ÇÒÐÄѪ¹Ü²»Á¼Ê¼þ·¢ÉúÂʸüµÍ¡£Õ⽫ΪÅàĪɳëÄÔÚ·Ç͸ÎöCKDƶѪ»¼ÕßÖеÄÓ¦ÓÃÌṩÓÐÁ¦Ö§³Ö¡£

    ¹ØÓÚÊ¥ÂÞÀ³?

    Ê¥ÂÞÀ³?ÊǵÏÍþÖƵÏÍþ¹ú¼Ê×ÔÖ÷Ñз¢µÄÈ«ÇòΨһ»ñÅúÉÏÊеÄEPOÄ£ÄâëÄ£¬ÎªÐÂÐͳ¤Ð§ESAÀàµÏÍþ¹ú¼ÊÎʥÂÞÀ³?ÓÚ2023Äê6Ô»ñÖйú¹ú¼ÒµÏÍþ¹ú¼ÊÆ·¼à¶½¹ÜÀí¾Ö£¨NMPA£©Åú×¼ÉÏÊУ¬ÊÊÓÃÓÚÖÎÁÆÒòCKDÒýÆðµÄƶѪ£¬°üÀ¨Î´½ÓÊÜESAÖÎÁƵijÉÈË·Ç͸Îö»¼Õߣ¬¼°ÕýÔÚ½ÓÊܶÌЧEPOÖÎÁƵijÉÈË͸Îö»¼Õß¡£Ê¥ÂÞÀ³?ÊǵÏÍþÖƵÏÍþ¹ú¼Ê»ñÅúÉÏÊеĵÚ7¿î´´ÐµÏÍþ¹ú¼Ê£¬Ò²ÊǵÏÍþÖƵÏÍþ¹ú¼ÊÊ׿îͬʱ»ñÅúÁ½ÏîÊÊÓ¦Ö¢µÄ´´ÐµÏÍþ¹ú¼Ê¡£


    ¹ØÓÚKidney International Reports

    Kidney International Reports£¨ÆÚ¿¯ISSN£º2468-0249 £¬ eISSN£º2468-0249£©Êǹú¼ÊÉöÔಡѧ»áµÄ¹Ù·½ÆÚ¿¯£¬ÊÇÒ»±¾Í¬ÐÐÆÀÉóµÄ¿ª·Å»ñÈ¡ÆÚ¿¯£¬ÖÂÁ¦ÓÚ·¢±íÓëÉöÔ༲²¡Ïà¹ØµÄÁìÏÈÑо¿ºÍ·¢Õ¹¡£¸ÃÔÓÖ¾µÄÖ÷ҪĿµÄÊÇΪ¸ÄÉÆÉöÔ༲²¡»¼ÕߵĻ¤Àí×ö³ö¹±Ï×£¬·¢±íÓë¼±ÐÔºÍÂýÐÔÉöÔ༲²¡¡¢ÖÕÄ©ÆÚÉöÔ༲²¡¡¢ÒÆÖ²¡¢Ëá¼î¡¢ÒºÌåºÍµç½âÖÊÎÉÂÒÒÔ¼°¸ßѪѹµÄ·¢²¡»úÖÆ¡¢ÆÀ¹ÀºÍ¹ÜÀíÏà¹ØµÄÔ­´´ÁÙ´²ºÍ¾«Ñ¡·­ÒëÎÄÕºͽÌÓýÄÚÈÝ¡£Kidney International Reports 2023Äê×îÐÂÆÚ¿¯Ó°ÏìÒò×ÓΪ5.7£¬ÔÚÈ«Çò126ÖÖ ¡°ÃÚÄòѧÓëÉöÔàѧ¡±ÆÚ¿¯ÖÐÅÅÃûµÚ11룬Q1Çø¡£


    ¹ØÓÚµÏÍþÖƵÏÍþ¹ú¼Ê

    µÏÍþÖƵÏÍþ¹ú¼ÊÊÇÖйúÁìÏȵĴ´ÐÂÇý¶¯ÐÍÖƵÏÍþ¹ú¼ÊÆóÒµ£¬ÏÂÊôºÀÉ­µÏÍþ¹ú¼ÊÒµ¡¢³£Öݺã°îµÏÍþ¹ú¼ÊÒµ¡¢µÏÍþÉúÎïÒ½µÏÍþ¹ú¼ÊµÈ×Ó¹«Ë¾£¬Öصã¹Ø×¢¿¹Ö×Áö¡¢¿¹¸ÐȾ¡¢ÖÐÊàÉñ¾­ÏµÍ³¡¢´úл¼°×ÔÉíÃâÒßµÈÖØ´ó¼²²¡ÖÎÁÆÁìÓò£¬ÖÂÁ¦ÓÚͨ¹ý³ÖÐø´´ÐÂÌá¸ßÈËÀàÉúÃüÖÊÁ¿¡£½ØÖÁ2024ÉÏ°ëÄ꣬¹«Ë¾ÒÑÉÏÊÐ7¿î´´ÐµÏÍþ¹ú¼Ê£¬´´Ð²úÆ·ÓªÊÕÕ¼±È´ï77.4%¡£¹«Ë¾Á¬Ðø¶àÄêλ¾ÓÈ«ÇòÖƵÏÍþ¹ú¼ÊÆóÒµ°ÙÇ¿¡¢ÖйúÒ½µÏÍþ¹ú¼ÊÑз¢²úÆ·Ïß×î¼Ñ¹¤ÒµÆóҵǰ3Ç¿£¬Êǹú¼ÒÖصã¸ßм¼ÊõÆóÒµ¡¢¹ú¼Ò¼¼Êõ´´ÐÂʾ·¶ÆóÒµ¡£¹«Ë¾ÓÚ2019Äê6ÔÂÔÚÏã¸ÛÁª½»Ëù¹ÒÅÆÉÏÊУ¨¹ÉƱ´úÂ룺03692.HK£©¡£¸ü¶àÐÅÏ¢Çë·ÃÎÊ£º/¡£

    ²Î¿¼×ÊÁÏ£º

    1. Zhang P, Jiang Y, Xu C et al. Pegmolesatide for the treatment of anemia in patients undergoing dialysis: a randomized clinical trial. EClinicalMedicine. 2023 Oct 28:65:102273. doi: 10.1016/j.eclinm.2023.102273. 

    2.Xie,Jianteng et al. Randomized Trial of Pegmolesatide for the Treatment of Anaemia in Patients with Non-Dialysis Chronic Kidney Disease. Kidney International Reports.2024.https://doi.org/10.1016/j.ekir.2024.12.002. In Press.


    ÉùÃ÷£º
    1¡¢µÏÍþÖƵÏÍþ¹ú¼Ê²»ÍƼöÈκÎδ»ñÅúµÏÍþ¹ú¼ÊƷʹÓûòδ»ñÅúÊÊÓ¦Ö¢ÓõÏÍþ¹ú¼Ê¡£

    2¡¢±¾ÐÂΟåÖеÄÒ½ÁÆÐÅÏ¢½ö¹©ÐÅÏ¢ºÍÐÂÎű¨µÀʹÓ㬲»ÓÃÓÚ¹ã¸æÄ¿µÄ£¬²»Òª½«ÆäÓÃÓÚÒ½ÁƱ£½¡»òÕï¶Ï½¨Òé¡£



    Ç°Õ°ÐÔ˵Ã÷



    ±¾ÐÂΟåÖ¼ÔÚÌṩ¹ØÓÚµÏÍþÖƵÏÍþ¹ú¼Ê¼¯ÍÅÓÐÏÞ¹«Ë¾¼°Æ丽Êô¹«Ë¾£¨°üÀ¨Æä×Ó¹«Ë¾£¬Í³³ÆΪ¡°µÏÍþÖƵÏÍþ¹ú¼Ê¡±£©µÄÐÅÏ¢¡£Ëü²»¹¹³É¶ÔµÏÍþÖƵÏÍþ¹ú¼Ê»òÈκÎͶ×ʽ¨ÒéµÄÐÅÏ¢Åû¶¡£

    ±¾ÐÂΟå°üº¬µÄÐÅÏ¢¿ÉÄÜ°üÀ¨ÓëµÏÍþÖƵÏÍþ¹ú¼ÊÒµÎñºÍ²úÆ·Ç°¾°¡¢¼Æ»®¡¢ÐÅÄî¡¢Ô¤ÆںͲßÂÔÏà¹ØµÄÇ°Õ°ÐÔÉùÃ÷¡£ÕâЩÉùÃ÷ÊÇ»ùÓÚÍƲâÐÔ¼ÙÉèµÄÔ¤²â£¬²¢²»±£Ö¤Î´À´µÄ±íÏÖ¡£ËüÃÇÊܵ½ÖîÈç¿Æѧ¡¢ÉÌÒµ¡¢ÕþÖΡ¢¾­¼Ã¡¢²ÆÎñ¡¢·¨ÂÉÒòËØÒÔ¼°¾ºÕù»·¾³ºÍÉç»áÌõ¼þµÈ·çÏպͲ»È·¶¨ÐÔµÄÓ°Ï죬ÕâЩÒòËغܶ඼ÊǵÏÍþÖƵÏÍþ¹ú¼ÊÎÞ·¨¿ØÖÆÇÒÄÑÒÔÔ¤²âµÄ£¬Òò´Ëʵ¼Ê½á¹û¿ÉÄÜÓë´Ë´¦ËùÊöÓÐÏÔÖø²îÒ죬ÇÒ¹ýÈ¥µÄ֤ȯ¼Û¸ñÇ÷ÊƲ»Ó¦×÷ΪδÀ´ÐÐÇéµÄÖ¸µ¼¡£Òò´Ë£¬Í¶×ÊÕßÔÚʹÓÃÕâЩÐÅÏ¢½øÐÐͶ×ʾö²ßʱӦ½÷É÷ÐÐÊ¡£¡°ÖÂÁ¦ÓÚ¡±¡°Ô¤ÆÚ¡±¡°ÏàÐÅ¡±¡°Ô¤²â¡±¡°Òâͼ¡±¡°Ô¤¼Æ¡±¡°¿ÉÄÜ¡±¡°½«¡±¡°Ó¦¸Ã¡±¡°¼Æ»®¡±¡°¼ÌÐø¡±¡°Ä¿±ê¡±¡°¿¼ÂÇ¡±¡°¹À¼Æ¡±¡°Ö¸µ¼¡±¡°Ç±ÔÚ¡±¡°×·Çó¡±ÒÔ¼°ÓÚÈκÎδÀ´¼Æ»®¡¢Ðж¯»òʼþµÄÌÖÂÛÖÐʹÓõÄÀàËÆ´ÊÓïºÍÊõÓ¾ù±íʾǰհÐÔÉùÃ÷¡£

    µÏÍþÖƵÏÍþ¹ú¼Ê²»³Ðŵ»ò±£Ö¤Ç°Õ°ÐÔÐÅÏ¢µÄ׼ȷÐÔ¡¢¼°Ê±ÐÔ»òÍêÕûÐÔ£¬²¢ÇÒ²»³Ðµ£¸üлòÐÞ¶©ÕâЩǰհÐÔÉùÃ÷µÄÒåÎñ¡£ÎÞÂÛÊǵÏÍþÖƵÏÍþ¹ú¼Ê»¹ÊÇÆäÈκζ­Ê¡¢Ô±¹¤»ò´úÀíÈË£¬¾ù²»¶ÔÈκÎÖ¤Ã÷²»×¼È·»òÎÞ·¨ÊµÏÖµÄÇ°Õ°ÐÔÉùÃ÷¸ºÔð£¬Ò²²»¶ÔÒòÒÀÀµ±¾ÐÂΟåÖÐÌṩµÄÐÅÏ¢¶ø²úÉúµÄÈκÎËðʧ»òË𺦸ºÔ𣬰üÀ¨µ«²»ÏÞÓÚÖ±½Ó¡¢Å¼È»¡¢¼ä½Ó»ò³Í·£ÐÔµÄË𺦡£

    ±¾ÐÂΟåÖеÄËùÓÐÐÅÏ¢¾ùΪ·¢²¼Ö®ÈÕµÄ×îÐÂÐÅÏ¢¡£µÏÍþÖƵÏÍþ¹ú¼Ê²»³Ðµ£Òòз¢Õ¹¡¢Î´À´Ê¼þ»òÆäËûÇé¿ö¶ø¸üлòÐÞ¶©ÕâЩÐÅÏ¢µÄÔðÈΣ¬³ý·Ç·¨ÂÉÒªÇó¡£´ËÍ⣬µÏÍþÖƵÏÍþ¹ú¼Ê±£ÁôÔÚÈκÎʱºòδ¾­Í¨Öª¶Ô±¾ÐÂΟåµÄÈ«²¿»ò²¿·ÖÄÚÈݽøÐиü¸Ä¡¢¸üÕý»òÖжϵÄȨÀû¡£¶ÔÓÚÌرðÓëÉÏÊй«Ë¾ÓйصÄÐÅÏ¢£¬¹«Ë¾¹ÄÀøͶ×ÊÕ߲ο¼µÏÍþÖƵÏÍþ¹ú¼Ê£¨03692.HK£©µÄ¹«¸æºÍ²ÆÎñ±¨¸æ¡£


    END

    ¡¾ÍøÕ¾µØͼ¡¿¡¾sitemap¡¿